Scott C. Chappel
Nessuna posizione attualmente
Profilo
Scott C.
Chappel is the founder of Arteaus Therapeutics LLC, which was founded in 2011.
He held the title of Chief Scientific Officer from 2011 to 2014.
Dr. Chappel's former jobs include Research Director at Integrated Genetics, Inc., Senior Vice President-Research at Diacrin, Inc. (Delaware), and Senior Vice President-Research at Dyax Corp.
He also held the title of Vice President-Research at EMD Serono, Inc. and Venture Partner at Apple Tree Venture Management Llc.
Dr. Chappel was Chief Scientific Officer at Annovation BioPharma, Inc. from 2013 to 2014, Chief Scientific Officer at OvaScience, Inc. from 2011 to 2013, and Chief Technology Officer at Surface Oncology, Inc. Dr. Chappel's education includes an undergraduate degree from The Pennsylvania State University and a doctorate from the University of Maryland Medical Center.
Precedenti posizioni note di Scott C. Chappel
Società | Posizione | Fine |
---|---|---|
SURFACE ONCOLOGY, INC. | Chief Tech/Sci/R&D Officer | 01/06/2018 |
Arteaus Therapeutics LLC
Arteaus Therapeutics LLC BiotechnologyHealth Technology Arteaus Therapeutics LLC develops therapies for migraine prevention. The company was founded by Dave Grayzel and Scott C. Chappel on July 15, 2011 and is headquartered in Cambridge, MA. | Founder | 01/01/2014 |
Annovation BioPharma, Inc.
Annovation BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Annovation BioPharma, Inc. develops pharmaceutical products in the field of anesthesia, sedation and sleep. It is developing a rapid-acting anesthesia called Rapidate. The firm's novel agents are designed to allow more precise control of anesthesia and enable safer treatment of patients undergoing surgical procedures. The company was founded in 2009 by Nicholas Barker and is headquartered in Parsippany, NJ. | Chief Tech/Sci/R&D Officer | 01/01/2014 |
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Chief Tech/Sci/R&D Officer | 31/07/2013 |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | Chief Tech/Sci/R&D Officer | 01/01/2011 |
Formazione di Scott C. Chappel
The Pennsylvania State University | Undergraduate Degree |
University of Maryland Medical Center | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 10 |
---|---|
Diacrin, Inc. (Delaware)
Diacrin, Inc. (Delaware) Medical SpecialtiesHealth Technology Diacrin, Inc. develops human cell transplant therapeutic products. The company is headquartered in Wilmington, DE. | Health Technology |
Dyax Corp.
Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
Annovation BioPharma, Inc.
Annovation BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Annovation BioPharma, Inc. develops pharmaceutical products in the field of anesthesia, sedation and sleep. It is developing a rapid-acting anesthesia called Rapidate. The firm's novel agents are designed to allow more precise control of anesthesia and enable safer treatment of patients undergoing surgical procedures. The company was founded in 2009 by Nicholas Barker and is headquartered in Parsippany, NJ. | Health Technology |
Arteaus Therapeutics LLC
Arteaus Therapeutics LLC BiotechnologyHealth Technology Arteaus Therapeutics LLC develops therapies for migraine prevention. The company was founded by Dave Grayzel and Scott C. Chappel on July 15, 2011 and is headquartered in Cambridge, MA. | Health Technology |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
Apple Tree venture Managemnet Llc//vc
Apple Tree venture Managemnet Llc//vc Investment ManagersFinance Apple Tree venture Managemnet LLC (Apple Tree Partners) is a venture capital firm founded by Seth Harrison in 1999. The firm is headquartered in New York with an additional offices in London, San Francisco and Cambridge. | Finance |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | Health Technology |
Integrated Genetics, Inc.
Integrated Genetics, Inc. Pharmaceuticals: MajorHealth Technology Part of Laboratory Corp. of America Holdings, Integrated Genetics, Inc. is a pharmaceutical preparations company. The private company is based in Framingham, MA. The company was founded by Robert J. Carpenter. | Health Technology |
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Health Technology |
Surface Oncology, Inc.
Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Scott C. Chappel